Literature DB >> 32247602

Less guessing, more evidence in identifying patients least fit for cytoreductive surgery in advanced ovarian cancer: A triage algorithm to individualize surgical management.

Deepa Maheswari Narasimhulu1, Amanika Kumar1, Amy L Weaver2, Carrie L Langstraat1, William A Cliby3.   

Abstract

OBJECTIVE: We previously reported an algorithm that identifies women at high risk of postoperative morbidity & mortality (M/M) as a tool to triage between neoadjuvant chemotherapy and primary surgery for epithelial ovarian cancer (EOC). We sought to independently validate its performance using multicenter data.
METHODS: Women who underwent surgery for stage IIIC/IV EOC between 1/1/2014 and 12/31/2017 were identified from the National Surgical Quality Improvement Program database and classified as "high risk" or "triage appropriate" using our algorithm. Outcomes were compared between triage appropriate and high-risk women using the chi-square test.
RESULTS: 1777 women met inclusion criteria; the mean age was 62.6 years and 81.9% had stage IIIC disease. Nationally, the surgical complexity scores were low (69.8% low, 25.2% intermediate and 5.0% high). "High risk" women had 2-fold higher rate of severe 30-day complication or death (6.2% vs 3.5%; p = 0.01), a 3-fold higher rate of 30-day mortality (1.4% vs 0.5%; p = 0.08), and a higher risk of death following a severe complication (11.1% vs. 0%, p = 0.11). A sensitivity analysis excluding women with unknown albumin who didn't meet other high risk criteria showed similar results: severe 30-day complications or death (6.2% vs 3.5%; p = 0.02) and 30-day mortality (1.4% vs 0.3%; p = 0.04) for "high risk" vs "triage appropriate" women.
CONCLUSIONS: Primary cytoreductive surgery to minimal residual disease remains the goal for EOC. We verify that our algorithm can identify women at risk of M/M using national multicenter data, despite a low complexity surgical setting and using 30-day mortality (vs. 90-day). Objective surgical risk assessment for ovarian cancer should be standard of care and can be incorporated into practice using the Mayo triage algorithm.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Epithelial ovarian cancer; Mayo triage algorithm; Morbidity and mortality; Primary debulking surgery

Mesh:

Year:  2020        PMID: 32247602      PMCID: PMC7293555          DOI: 10.1016/j.ygyno.2020.03.024

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  14 in total

1.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial.

Authors:  Sean Kehoe; Jane Hook; Matthew Nankivell; Gordon C Jayson; Henry Kitchener; Tito Lopes; David Luesley; Timothy Perren; Selina Bannoo; Monica Mascarenhas; Stephen Dobbs; Sharadah Essapen; Jeremy Twigg; Jonathan Herod; Glenn McCluggage; Mahesh Parmar; Ann-Marie Swart
Journal:  Lancet       Date:  2015-05-19       Impact factor: 79.321

2.  Predictors of postoperative morbidity after cytoreduction for advanced ovarian cancer: Analysis and management of complications in upper abdominal surgery.

Authors:  Pierluigi Benedetti Panici; Violante Di Donato; Margherita Fischetti; Assunta Casorelli; Giorgia Perniola; Angela Musella; Claudia Marchetti; Innocenza Palaia; Pasquale Berloco; Ludovico Muzii
Journal:  Gynecol Oncol       Date:  2015-03-28       Impact factor: 5.482

3.  Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.

Authors:  Ryan J Spencer; Kari E Hacker; Jennifer J Griggs; Laurel W Rice; R Kevin Reynolds; Shitanshu Uppal
Journal:  Obstet Gynecol       Date:  2017-08       Impact factor: 7.661

4.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer.

Authors:  Ignace Vergote; Claes G Tropé; Frédéric Amant; Gunnar B Kristensen; Tom Ehlen; Nick Johnson; René H M Verheijen; Maria E L van der Burg; Angel J Lacave; Pierluigi Benedetti Panici; Gemma G Kenter; Antonio Casado; Cesar Mendiola; Corneel Coens; Leen Verleye; Gavin C E Stuart; Sergio Pecorelli; Nick S Reed
Journal:  N Engl J Med       Date:  2010-09-02       Impact factor: 91.245

5.  An analysis of patients with bulky advanced stage ovarian, tubal, and peritoneal carcinoma treated with primary debulking surgery (PDS) during an identical time period as the randomized EORTC-NCIC trial of PDS vs neoadjuvant chemotherapy (NACT).

Authors:  Dennis S Chi; Fernanda Musa; Fanny Dao; Oliver Zivanovic; Yukio Sonoda; Mario M Leitao; Douglas A Levine; Ginger J Gardner; Nadeem R Abu-Rustum; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2011-09-13       Impact factor: 5.482

6.  Using an evidence-based triage algorithm to reduce 90-day mortality after primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Deepa M Narasimhulu; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2019-08-08       Impact factor: 5.482

7.  Impact of a structured quality management program on surgical outcome in primary advanced ovarian cancer.

Authors:  Philipp Harter; Zelal M Muallem; Christine Buhrmann; Dietmar Lorenz; Christine Kaub; Rita Hils; Stefan Kommoss; Florian Heitz; Alexander Traut; Andreas du Bois
Journal:  Gynecol Oncol       Date:  2011-03-17       Impact factor: 5.482

8.  Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.

Authors:  Anna Fagotti; Gabriella Ferrandina; Giuseppe Vizzielli; Francesco Fanfani; Valerio Gallotta; Vito Chiantera; Barbara Costantini; Pasquale Alessandro Margariti; Salvatore Gueli Alletti; Francesco Cosentino; Lucia Tortorella; Giovanni Scambia
Journal:  Eur J Cancer       Date:  2016-03-19       Impact factor: 9.162

9.  Improved progression-free and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm.

Authors:  Dennis S Chi; Eric L Eisenhauer; Oliver Zivanovic; Yukio Sonoda; Nadeem R Abu-Rustum; Douglas A Levine; Matthew W Guile; Robert E Bristow; Carol Aghajanian; Richard R Barakat
Journal:  Gynecol Oncol       Date:  2009-04-23       Impact factor: 5.482

10.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

View more
  4 in total

1.  Comparison of Survival Between Primary Debulking Surgery Versus Neoadjuvant Chemotherapy for Ovarian Cancers in a Personalized Treatment Cohort.

Authors:  Zheng Feng; Hao Wen; Ruimin Li; Shuai Liu; Yi Fu; Xiaojun Chen; Rui Bi; Xingzhu Ju; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-02-10       Impact factor: 6.244

2.  Practical guidelines for triage to neoadjuvant chemotherapy in advanced ovarian cancer: Big risk, big reward…or too much risk?

Authors:  Kara Long Roche; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2020-06       Impact factor: 5.482

3.  Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer.

Authors:  Nicholas Cardillo; Eric J Devor; Silvana Pedra Nobre; Andreea Newtson; Kimberly Leslie; David P Bender; Brian J Smith; Michael J Goodheart; Jesus Gonzalez-Bosquet
Journal:  Cancers (Basel)       Date:  2022-07-21       Impact factor: 6.575

4.  Appropriate triage allows aggressive primary debulking surgery with rates of morbidity and mortality comparable to interval surgery after chemotherapy.

Authors:  Deepa M Narasimhulu; Aneesa Thannickal; Amanika Kumar; Amy L Weaver; Michaela E McGree; Carrie L Langstraat; William A Cliby
Journal:  Gynecol Oncol       Date:  2020-12-31       Impact factor: 5.482

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.